Authors' objectives: Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late, once it has spread to other parts of the body and is difficult to treat. KRAS mutation in the genes of lung cancer cells can stop some treatments from working effectively. Selumetinib is a new drug for the treatment of KRAS mutation-positive non-small cell lung cancer. It is administered as a tablet taken once a day alongside chemotherapy. Selumetinib is currently being studied to see how well it works and whether it is safe to use. If selumetinib is licensed, it will offer a new treatment option for patients with lung cancer after a first treatment has stopped working. This group of patients often only survive for less than a year.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/selumetinib-for-kras-mutation-positive-advanced-non-small-cell-lung-cancer-second-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)